287 related articles for article (PubMed ID: 24143858)
1. Two-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice.
Meng H; Zhao Y; Dong J; Xue M; Lin YS; Ji Z; Mai WX; Zhang H; Chang CH; Brinker CJ; Zink JI; Nel AE
ACS Nano; 2013 Nov; 7(11):10048-65. PubMed ID: 24143858
[TBL] [Abstract][Full Text] [Related]
2. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice.
Meng H; Wang M; Liu H; Liu X; Situ A; Wu B; Ji Z; Chang CH; Nel AE
ACS Nano; 2015; 9(4):3540-57. PubMed ID: 25776964
[TBL] [Abstract][Full Text] [Related]
3. pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth in Pancreatic Cancer.
Ray P; Dutta D; Haque I; Nair G; Mohammed J; Parmer M; Kale N; Orr M; Jain P; Banerjee S; Reindl KM; Mallik S; Kambhampati S; Banerjee SK; Quadir M
Mol Pharm; 2021 Jan; 18(1):87-100. PubMed ID: 33231464
[TBL] [Abstract][Full Text] [Related]
4. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
5. A novel gemcitabine derivative-loaded liposome with great pancreas-targeting ability.
Li PW; Luo S; Xiao LY; Tian BL; Wang L; Zhang ZR; Zeng YC
Acta Pharmacol Sin; 2019 Nov; 40(11):1448-1456. PubMed ID: 31015736
[TBL] [Abstract][Full Text] [Related]
6. Triple drugs co-delivered by a small gemcitabine-based carrier for pancreatic cancer immunochemotherapy.
Sun J; Wan Z; Chen Y; Xu J; Luo Z; Parise RA; Diao D; Ren P; Beumer JH; Lu B; Li S
Acta Biomater; 2020 Apr; 106():289-300. PubMed ID: 32004652
[TBL] [Abstract][Full Text] [Related]
7. Irinotecan Delivery by Lipid-Coated Mesoporous Silica Nanoparticles Shows Improved Efficacy and Safety over Liposomes for Pancreatic Cancer.
Liu X; Situ A; Kang Y; Villabroza KR; Liao Y; Chang CH; Donahue T; Nel AE; Meng H
ACS Nano; 2016 Feb; 10(2):2702-15. PubMed ID: 26835979
[TBL] [Abstract][Full Text] [Related]
8. Co-delivery of microRNA-21 antisense oligonucleotides and gemcitabine using nanomedicine for pancreatic cancer therapy.
Li Y; Chen Y; Li J; Zhang Z; Huang C; Lian G; Yang K; Chen S; Lin Y; Wang L; Huang K; Zeng L
Cancer Sci; 2017 Jul; 108(7):1493-1503. PubMed ID: 28444967
[TBL] [Abstract][Full Text] [Related]
9. Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma.
Wu L; Zhang F; Chen X; Wan J; Wang Y; Li T; Wang H
ACS Appl Mater Interfaces; 2020 Jan; 12(3):3327-3340. PubMed ID: 31872760
[TBL] [Abstract][Full Text] [Related]
10. Lipid-based mesoporous silica nanoparticles: a paradigm shift in management of pancreatic cancer.
Bellapu KK; Joga R; Kannan BR; Yerram S; Varpe P; Mergu T; Vasu PY; Srivastava S; Kumar S
Pharm Pat Anal; 2023 Nov; 12(6):261-273. PubMed ID: 38214201
[TBL] [Abstract][Full Text] [Related]
11. Development and In Vitro Evaluation of Long Circulating Liposomes for Targeted Delivery of Gemcitabine and Irinotecan in Pancreatic Ductal Adenocarcinoma.
Deodhar S; Dash AK; North EJ; Hulce M
AAPS PharmSciTech; 2020 Aug; 21(6):231. PubMed ID: 32778980
[TBL] [Abstract][Full Text] [Related]
12. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
[TBL] [Abstract][Full Text] [Related]
13. Micelle Mixtures for Coadministration of Gemcitabine and GDC-0449 To Treat Pancreatic Cancer.
Karaca M; Dutta R; Ozsoy Y; Mahato RI
Mol Pharm; 2016 Jun; 13(6):1822-32. PubMed ID: 26981724
[TBL] [Abstract][Full Text] [Related]
14. pH-sensitive stearoyl-PEG-poly(methacryloyl sulfadimethoxine) decorated liposomes for the delivery of gemcitabine to cancer cells.
Bersani S; Vila-Caballer M; Brazzale C; Barattin M; Salmaso S
Eur J Pharm Biopharm; 2014 Nov; 88(3):670-82. PubMed ID: 25157908
[TBL] [Abstract][Full Text] [Related]
15. PEG-b-poly (carbonate)-derived nanocarrier platform with pH-responsive properties for pancreatic cancer combination therapy.
Ray P; Confeld M; Borowicz P; Wang T; Mallik S; Quadir M
Colloids Surf B Biointerfaces; 2019 Feb; 174():126-135. PubMed ID: 30447521
[TBL] [Abstract][Full Text] [Related]
16. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
[TBL] [Abstract][Full Text] [Related]
17. Co-Delivery Using pH-Sensitive Liposomes to Pancreatic Cancer Cells: the Effects of Curcumin on Cellular Concentration and Pharmacokinetics of Gemcitabine.
Xu H; Li Y; Paxton JW; Wu Z
Pharm Res; 2021 Jul; 38(7):1209-1219. PubMed ID: 34189639
[TBL] [Abstract][Full Text] [Related]
18. Biodegradable, pH-Sensitive Hollow Mesoporous Organosilica Nanoparticle (HMON) with Controlled Release of Pirfenidone and Ultrasound-Target-Microbubble-Destruction (UTMD) for Pancreatic Cancer Treatment.
Gao F; Wu J; Niu S; Sun T; Li F; Bai Y; Jin L; Lin L; Shi Q; Zhu LM; Du L
Theranostics; 2019; 9(20):6002-6018. PubMed ID: 31534533
[TBL] [Abstract][Full Text] [Related]
19. PEGylated liposomal Gemcitabine: insights into a potential breast cancer therapeutic.
Papa AL; Sidiqui A; Balasubramanian SU; Sarangi S; Luchette M; Sengupta S; Harfouche R
Cell Oncol (Dordr); 2013 Dec; 36(6):449-57. PubMed ID: 24081907
[TBL] [Abstract][Full Text] [Related]
20. Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma.
Madamsetty VS; Pal K; Dutta SK; Wang E; Thompson JR; Banerjee RK; Caulfield TR; Mody K; Yen Y; Mukhopadhyay D; Huang HS
Bioconjug Chem; 2019 Oct; 30(10):2703-2713. PubMed ID: 31584260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
